ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1086

Characteristics and Outcomes of Patients with ANCA Associated Vasculitis Treated with Plasma Exchange: An Analysis of the National Inpatient Sample Database
Abstract Number: 1087

Identification of Novel Proteomic Biomarkers of Disease Activity in ANCA-Associated Vasculitis Using a High Throughput Approach
Abstract Number: 1088

Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Abstract Number: 1089

Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Abstract Number: 1090

Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Abstract Number: 1091

IgG Antibody Subclass Glycan Modifications in Patients with ANCA-Associated Vasculitis in Active vs Remission States – a Proof-of-Concept Study
Abstract Number: 1092

Intrarenal Synthesis of Complement C3 Localized to Distinct Vascular Compartments in ANCA-associated Renal Vasculitis
Abstract Number: 1093

ANCA Associated Vasculitis: Online CME Improves Rheumatologists’ Knowledge and Confidence
Abstract Number: 1094

Mechanical Loading-induced BHLHE40 Promotes Inflammatory Arthritis
Abstract Number: 1095

A20(Tnfaip3) in Keratinocytes Restricts an Early Antiviral Gene Program Associated with Psoriatic Skin and Joint Disease
Abstract Number: 1096

IL-23 Induced Growth Differentiation Factor 15 Contributes to Trabecular Bone Loss, but Does Not Affect Skin, Gut or Joint Inflammation in Psoriatic Arthritis
Abstract Number: 1097

Intrinsic STAT1 Deficiency Underlies Proinflammatory Imprint of Naive CD4+ T Cells in Spondyloarthritis
Abstract Number: 1098

Perceived Barriers and Opportunities to Accessing Rheumatoid Arthritis Care on Navajo Nation: The Primary Care Providers’ Perspectives
Abstract Number: 1099

Empowering Patients with Lupus Through Their Photographs: Application of the Photovoice Method to Understand Social Determinants of Health
Abstract Number: 1100

Racial Differences in Clinical Trial Perceptions Among a Large, Predominantly Black Cohort of Patients with Systemic Lupus Erythematosus in the Southeastern United States

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].